Latest tumor Stories
New minimally invasive therapy safely treats complex cancers, leaves healthy tissues intact NEW ORLEANS, April 14, 2013 /PRNewswire-USNewswire/ -- Highlights Minimally invasive electrical pulse treatment pokes microscopic holes in cancerous tumors without hurting healthy nearby tissue, research suggests. IRE appears to be beneficial in treating pancreatic, liver, lung and other challenging cancers, according to a study being presented at SIR 2013. While surgery and other...
Mount Sinai researchers present targets, treatments for prostate, colon, and ovarian cancer at the American Association for Cancer Research Annual Meeting Research on a soy-based treatment for colorectal cancer, a promising agent in ovarian cancer, and a new drug target for advanced prostate cancer was presented at the American Association for Cancer Research 2013 Annual Meeting. The meeting took place April 6-10, 2013 in Washington, DC. Natural Product From Soy May Be Effective in...
Some breast tumor circulating cells in the bloodstream are marked by a constellation of biomarkers that identify them as those destined to seed the brain with a deadly spread of cancer, said researchers led by those at Baylor College of Medicine in a report that appears online in the journal Science Translational Medicine. "What prompted us to initiate this study was our desire to understand the characteristics of these cells," said Dr. Dario Marchetti, professor of pathology at BCM,...
Study of RNA interference drug presented at AACR Annual Meeting 2013 The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen). Early results from the phase I, first in-human study of an RNA interference (RNAi) drug were announced during the American Association for Cancer Research (AACR) Annual Meeting 2013, April 6-10,...
Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue. "Papillary thyroid cancer is the most common endocrine...
Diverse pipeline reflected in four molecules targeting key cancer pathways WASHINGTON, April 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) unveiled data from four key molecules that represent the next generation of its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. from April 6-10. The data reflect Lilly's diverse oncology pipeline via molecules that target several pathways that are among the most common...
Is the era of targeted therapy for breast cancer at hand? It could be, said experts at the Lester and Sue Smith Breast Center at Baylor College of Medicine – at least for a certain population of women. In a report that appears online today in the Journal of Clinical Oncology, the researchers have shown that a subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of...
BALTIMORE and HAMBURG, Germany, April 9, 2013 /PRNewswire/ -- A study presented at the AACR Annual Meeting 2013 indicates that a DNA blood test using Inostics' BEAMing Digital PCR can detect more mutations associated with secondary drug resistance in GIST patients than testing conventional biopsies. Therapies targeted to specific cancer-causing mutations may be the most promising strategy in cancer treatment. However, inter- and intra-tumor heterogeneity pose a...
TSX Venture: QPT EDMONTON, April 8, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer. The technology was developed by Professor Manuel Penichet and Dr. Tracy...
NKTR-214 Demonstrates Improved Efficacy in Resistant Preclinical Melanoma Model Through Preferential Activation of Tumor Killing Immune Cell Subtype SAN FRANCISCO, April 7, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research (AACR) Annual Meeting. NKTR-214 is a new immunocytokine that is being developed...
